Topics:

Oncology and Hematology News and Journal Articles

FDA Approves Ramucirumab for Second-Line Treatment of mCRC

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Recent Content

A revised International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS) could allow for more precise staging for children and adolescents with NHL.

Advocacy is about making sure that our lawmakers enact the best healthcare policies for our patients. Just as we have a duty to our patients in the clinic, we also have a duty to advocate for laws that benefit patients’ health.

Trabectedin failed to improve progression-free survival outcomes compared to doxorubicin as first-line therapy for advanced/metastatic soft-tissue sarcoma.

The multi-targeted TKI lenvatinib showed promise in a phase II trial of patients with advanced, radioiodine-refractory, differentiated thyroid cancer.

This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.

A 30-year-old man who recently underwent induction chemotherapy for bone marrow transplant is admitted with neutropenia and right lower-quadrant abdominal pain. What is your diagnosis?

Understanding treatment-induced neurotoxicity can be difficult when treating patients with central nervous system (CNS) malignancies.

By clicking Accept, you agree to become a member of the UBM Medica Community.